Treatment effects of docetaxe or irinotecan combined with cisplatin on patients with advanced non-small cell lung cancer
10.3760/cma.j.issn.1006-9801.2010.09.007
- VernacularTitle:多西紫杉醇或伊立替康联合顺铂治疗晚期非小细胞肺癌
- Author:
Ailian ZHU
;
Ming GAO
- Publication Type:Journal Article
- Keywords:
Carcinoma,non-small-cell lung;
Cisplatin;
Docetaxe;
Irinotecan
- From:
Cancer Research and Clinic
2010;22(9):598-600
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe and compare the recent objective response rate and adverse reaction of docetaxe and irinotecan combined with cisplatin in the treatment of advanced non-small cell lung cancer (NSCLC). Methods Sixty-five patients with advanced NSCLC were randomly divided into goup A consisted of 33 patients received docetaxe plus capecitabine and group B consisted of 32 patients received irinotecan plus capecitabine with a 21-day regimen. Two or more cycles of chemotherapy were completed in each group. Results Sixty-five patients were assessable for efficacy and toxicities. In group A, 2 patients achieved complete response, 13 patients partial response, overall response rate was 45.45 % and the median progression-free survival (PFS) was 10.1 months. In group B, 2 patients achieved complete response, 12 patients partial response, overall response rate was 43.75 %, and the median PFS was 10.2 months. The efficacy and PFS were not significantly different between the two groups(P ＞0.05). The most common adverse reactions were myelosuppression and gastrointestinal response in the two groups. The main adverse reactions is anemia in group A and diarrhoea in group B. Patients in group A experienced more anemia. On the contrary,the rate in group B was more increased. No chemotherapy-related death was observed. Conclusion The effects of docetaxe combined with cisplatin and irinotecan combined with cisplatin in the treatment of advanced NSCLC are comparable and equivalent, and the adverse reactions can be tolerated.
